Sellas Life Sciences is trading at $10.99, up 5.88%, with no clear company-specific catalyst identified for the October 29 rebound.
- Major U.S. indices are lower, so broader-market strength does not explain the gain.
- On October 28, Sellas announced the Phase 3 REGAL trial reached its 80th event, triggering final analysis; preliminary topline results are expected this quarter. The update disclosed no efficacy results and was linked to the prior session’s selloff, not today’s rise.